Clinical predictors for the prognosis of myasthenia gravis

BMC Neurology

Table 2 Secondary generalization of ocular myasthenia gravis

	OMG-R	SGMG	NA	P-value	Time of generalization (month)			P-value	First symptom of generalization Limb bulbar both NA				P-value
	OMG-R	SGMG	NA	P-value	≤6	7–24	NA	P-value	First symptom of generalization Limb bulbar both NA				P-value
Sample size	6	34	19		21	6	7		8	13	6	7
Age of onset(year)^c	6	34	19	0.017	21	6	7	0.588	8	13	6	7	0.329
Age of onset(year)^d
≤ 40	5	10		0.021	7	1	2	0.406	2	2	3	3	0.277
> 40	1	24			14	5	5		6	11	3	4
Sex
Male	2	14		0.544	8	4	2	0.219	4	5	3	2	0.834
Female	4	20			13	2	5		4	8	3	5
Thymus
Normal	2	3		0.058	1	1		0.027^a	2	0	0	1	0.152
Thymic	2	20			15	1			5	9	3	3
hyperplasia
Thymoma	0	10			5	4			1	3	3	3
NA	2	1			0	0			0	1	0	0
Other autoimmune disease
No	6	21		0.077	14	3	4	0.387	6	6	4	5	0.390
Yes	0	13			7	3	3		2	7	2	2
Symptom of OMG onset
Sample size	6	34				34				34
Ptosis	5	20		0.487	12	1	7	0.027^b	4	8	2	6	0.376
Diplopia	0	3			3	0	0		2	0	1	0
Both	1	11			6	5	0		2	5	3	1
Ptosis
Sample size	5	20				20			20
Left	1	2		0.404	1	1	0	0.400	0	1	0	1	1.000
Right	1	8			6	0	2		1	4	1	2
Bilateral	0	5			2	0	3		1	2	0	2
NA	3	5			5				5

NA: not available; OMG-R: patients presenting with pure ocular MG and remaining with only ocular manifestations during the first two years after disease onset; SGMG: patients presenting with pure ocular MG at disease onset and developed secondary generalized symptoms and signs during the first two years after onset; Both: concurrence of ptosis and diplopia as the first onset symptom of OMG generalization
^a: compared between thymic hyperplasia and other thymus histology (including normal thymus and thymoma)
^b: compared between concurrence and not concurrence of ptosis and diplopia
^c Age at onset was not divided into two groups (statistical analysis using correlation matrix)
^d Age at onset was divided into two groups (statistical analysis using chi-square or Fisher exact test)

ISSN: 1471-2377